Innovative medicine blows! Hengrui's half-year revenue of 10 billion Chinese biopharmaceuticals 12.5 billion

the wind, the wind of innovation seems to be blowing harder and harder.Recently, a number of pharmaceutical companies, including Junshi Bio, Baiji Shenzhou, Gori Pharmaceuticals, Xinda Bio and Hengrui Pharmaceuticals, have released their first-half results, as a number of new biopharmaceutical companies with innovative drugs for profit, they have achieved good results since the listing.'s new biopharmaceers companies surged Junshi Bio's semi-annual report showed revenue of 309 million yuan in the first half of the year, while Junshi Bio's 2018 annual report showed a loss of 724 million yuan. The most important reason for the performance reversal is of course the continuous release of its PD-1 variety Terriple monoanti (commodity name: Toyi), which Junshi Bio reported in its semi-annual report that the sales revenue of Terripley monoantitor accounted for 99.69 percent.Innovatoric drugs continue to drive the growth of the company's performance, The performance of Junshi Bio is only a microcosm of a number of biological pharmaceutical companies last year, and Junshi Bio similar Xinda Bio also announced on the evening of August 28 2019 semi-annual report, the reporting period, Xinda Bio achieved total revenue of about 346 million yuan. Among them, this year's first commercialized product Xindili single resistance (commodity name: Daboshu) generated sales of 332 million yuan.of course, Xinda Bio's sales costs are still higher than the industry average, and during the reporting period, Thyda Bio's sales and marketing expenses amounted to about $280 million, accounting for about 80.9% of revenue. By comparison, it can be found that the first half of the sales cost of Junshi biological only 111 million yuan, less than half of Xinda biological.with the continuous commercialization of PD-1 products, market competition will become more and more intense, Xinda Bio's sales costs may be further increased.And Junshi Biological and Xinda Biological Institute is different, Baiji Shenzhou has not been able to support their own performance of the product market, although Baiji Shenzhou also has PD-1 products for Reilly Zhu single resistance in research, but has not yet been commercialized, according to the previous Baiji Shenzhou China General Manager Wu Xiaobin said, for Reilly Zhu single anti-market time is expected to wait until the end of this year., which is not profitable, has begun to reduce its losses compared with the previous year, with first-half revenues of about $321 million, up 276.3 percent from a year earlier, according to the 2019 mid-year results released on August 29. Net loss was $254 million, down about 3.4 percent from a year earlier.addition, baiji Shenzhou announced on August 21st that the FDA had accepted the listing application for its BTK inhibitor Zebutini and granted priority review eligibility. Zebtini is a BTK inhibitor, potential best-in-class, which the FDA has awarded fast-track eligibility (WM) and breakthrough therapy (r/r-MCL), meaning Zebtini becomes the first NCE in China to file a listing application with the United States.traditional giants are not willing to show weakness it can be seen that the two listed in Hong Kong shares of the emerging biopharmaceers are currently the main profits from the approved listed PD-1 products. In fact, in addition to Junshi Bio and Xinda Bio, the traditional pharmaceutical leader Hengrui Pharmaceuticals PD-1 product Karelli Zhu single resistance (commodity name: Erica) was also approved at the end of May this year, becoming the third pharmaceutical company in China to get the PD-1 product listing approval.According to the data, Hengrui Pharmaceuticals has invested about 504 million yuan in research and development costs in Karelli Zhu monoanti, and 33 clinical trials are under way for different adaptations and treatment options. At present, Karelli pearl single anti-pricing specifications of 200mg per bottle in 198,000 yuan, compared with the Junshi biological, Thyda biological and other peer competition is undoubtedly higher than a ladder. How to compete with Junshi Bio and Xinda Bio in the future will test the wisdom of Hengrui Pharmaceutical sales team.In fact, as the largest pharmaceutical company by market capitalization in China, Hengrui Pharmaceuticals has also begun to shift its research and development focus to innovative pharmaceuticals, according to the semi-annual report, in the first half of 2019 Hengrui Pharmaceuticals invested 1,484 million yuan in research and development, an increase of 49.13 percent over the same period last year, and the proportion of research and development investment in sales revenue reached 14.80 percent.Specific products, according to the semi-annual report shows that, including the aforementioned Carelli pearl monoanti, Hengrui Pharmaceuticals in the innovative drugs are innovative drugs are erytheb, apatinib, thiaperic non-gesting and pyridoxine and other 5 products were approved for market this year, and formed an annual application for innovative drugs clinical, every 2-3 years there is an innovative drug market situation.'s innovations were finally reflected in its performance, with revenue of RMB10,026 million in the first half of the year, up 29.19 percent, and net profit of RMB2,412 million, up 26.32 percent from the same period last year, according to the 2019 semi-annual report released by Hengrui Pharmaceuticals on Aug. 29. It is worth noting that this is the first time Hengrui half-yearly revenue exceeded the 10 billion yuan mark, net profit also passed the 2 billion yuan threshold. In fact, Hengrui Pharmaceuticals itself said that the first half of the steady growth of the main drivers include two factors: first, the harvest of innovative results, from the source to drive revenue, and second, product structure optimization, and thus achieve a diversified and collaborative layout.In addition to Hengrui Pharmaceuticals, China Biopharmaceuticals, which also has a research and development base in Lianyungang, also reported significant growth in its first-half results, with revenue of about 12.527 billion yuan, up 28.8% year-on-year, and net profit of about 1.444 billion yuan, up 5.8% year-on-year, according to the mid-2019 results report released by China Biopharmaceuticals on the evening of August 28.of these new drugs have brought new growth points to China Biopharmaceuticals. Among them, the first half of the first half of the cancer drug sector sales increased 146% year-on-year to 2.57 billion yuan, accounting for about 20.5% of the company's overall sales revenue.of foscovir soft tissue sarcoma was also approved in July this year, and the approval of new adaptations in the future will further boost Ffokwei's sales growth. In addition, in the first half of 2019, new varieties of cancer drugs Chiping (boronitezomy injection) and Ansien (lynamine tablets) recorded sales revenue of 78 million yuan and 97 million yuan, respectively. Can be seen that whether it is Hengrui Pharmaceuticals or China Biopharmaceuticals, in the case of enterprises themselves have become bigger and stronger, it will be essential to research and development innovation as their own survival value and development direction, according to the semi-annual reports of the two enterprises show that research and development investment is higher than the market average. Among them, Hengrui Pharmaceutical invested 1,484 million yuan in research and development in the first half of the year, an increase of 49.13 percent over the same period last year, and its research and development investment accounted for 14.80 percent of revenue, which strongly supported its project research and development and innovation development. innovation should be an important means for pharmaceutical is it the mouth of innovative pharmaceutical companies? The answer seems to be. highlight of the Drug Administration Law passed by the Standing Committee of the National People's Congress on August 26th was to encourage drug innovation and speed up the launch of new drugs. Specific measures include optimizing the review process, improving the efficiency of the review, and changing the clinical trial approval system, which had been in place for many years, to an implied licensing system. data, from 2007 to the first half of 2019, 700 domestic enterprises declared clinical trials or production of innovative drugs, hundreds of innovative drugs. At the same time, the domestic innovative drug market capacity is also expanding. In the past 6 years, the compound growth rate of innovative drugs has reached 27%. In 2018, the total domestic sales of innovative drugs exceeded 11 billion yuan. Innovating drugs support the continued progress of China's pharmaceutical industry, but new drug research and development should also actively seek differentiation, after all, a drug or a target market is so large, if all invested in a single field, the competitive environment will be very fierce, in the case of wolf meat, can grab their own share is also unknown. For example, the above mentioned several enterprises, the direction of their research and development has a certain convergence, Junshi Biological, Baiji Shenzhou, Xinda Bio and Hengrui Pharmaceuticals have PD-1 products in research, plus foreign Opdivo and K medicine (Keytruda), the current domestic market has six products in the study (sales), cake would have been fixed, more and more players to join, is bound to become three monks without water to eat risk. In fact, such views have been put forward, August 27 in Lianyungang City, the 2019 National Pharmaceutical Industry Information Conference held at a sub-forum, a well-known domestic innovative pharmaceutical company head said: "At present, in addition to the five markets of PD-1 products, there are still many varieties in research, but really need so many products?" While PD-1 therapy is one of the innovations of the future, no one can make money once so many businesses pour in. innovation should be a means, not an end, for innovative pharmaceutical companies, after all, for the enterprise itself, the ability to enhance survival is the key, and this is also the source of innovation strength. (Sina Pharmaceutical News)